In January 2005, the GSK agreement was amended to focus on 12 specific programs: XL647, XL999, XL784, XL880, XL820, XL844, XL184, XL281, XL418, XL228 and two earlier-stage programs, from which GSK had the right to make its development elections. Exelixis retains rights to collaboration compounds not selected by GSK, subject to payment to GSK of a low, single-digit royalty on certain "Refused Candidates" that GSK elects not to choose with its development election which Exelixis thereafter successfully commercializes. Under the amended agreement, GSK may pay selection milestones, additional development-related milestones, and double-digit royalties on product sales with respect to selected compounds. Exelixis has certain co-promotion rights in North America for compounds selected by GSK for further development.
In August 2007, GSK requested to initiate its review of XL880 before
the compound reached proof-of-concept in phase 2 trials. Exelixis agreed to
this request and submitted the data report to GSK in September 2007. In
December 2007, GSK exercised its development option for XL880, triggering a
$35 million selection milestone, which offset a milestone payment
previously paid by GSK. GSK has the right to select one additional compound
for development and commercialization from remaining programs in clinical
development (XL184, XL281, XL228, XL820, and XL844) and if its election
decision is made for a compound submitted during the development term,
Exelixis would be owed a $55 million selection milestone, with the
|SOURCE Exelixis, Inc.|
Copyright©2008 PR Newswire.
All rights reserved